| Dr Brian Jonathan Lipman, MD | |
|
10001 S Eastern Ave Ste 307, Henderson, NV 89052 | |
| (702) 909-7170 | |
| (702) 909-7234 |
| Full Name | Dr Brian Jonathan Lipman |
|---|---|
| Gender | Male |
| Speciality | Infectious Disease |
| Experience | 41 Years |
| Location | 10001 S Eastern Ave Ste 307, Henderson, Nevada |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053367383 | NPI | - | NPPES |
| 2018176 | Medicaid | NV |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | 9172 (Nevada) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Saint Rose Dominican Hospitals - Siena Campus | Henderson, NV | Hospital |
| Saint Rose Dominican Hospitals - San Martin Campus | Las vegas, NV | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Brian Jonathan Lipman Md Pc | 6709987027 | 3 |
News Archive
Oxford Nanopore Technologies Ltd. announces that Clive G Brown, Chief Technology Officer, will present at the Advances in Genome Biology and Technology (AGBT) conference in Marco Island, Florida, on 17th February 2012 at 11.40am (EST) / 4.40pm (GMT).
The fragrances used in many household and skincare products can cause contact allergy when exposed to oxygen in the air, reveals research from the University of Gothenburg's Faculty of Science in conjunction with the University of Gothenburg to be presented at the dermatologist conference in Gothenburg.
Spectrum Pharmaceuticals, Inc., a commercial-stage biotechnology company with a primary focus in oncology and hematology, and TopoTarget A/S, today announced that the first patient has been dosed in a National Cancer Institute -sponsored Phase 1/2 trial of belinostat in combination with cisplatin, doxorubicin and cyclophosphamide in the first line treatment of advanced or recurrent thymic malignancies.
Scientists have combined two new "designer" forms of aspirin into a hybrid substance that appears more effective than either of its forebears in controlling the growth of several forms of cancer in laboratory tests. Their report on the new NOSH-aspirin, so named because it releases nitric oxide (NO) and hydrogen sulfide (H2S), appears in the journal ACS Medicinal Chemistry Letters.
Using some of the most advanced molecular sequencing tools available to evaluate COVID-19 rapid autopsy tissues, researchers have identified four major regulatory pathways, specific molecular effectors behind COVID-19 symptoms, and differences that drive diverging clinical courses among individual patients.
› Verified 7 days ago
| Entity Name | Brian Jonathan Lipman Md Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255533733 PECOS PAC ID: 6709987027 Enrollment ID: O20070730000875 |
News Archive
Oxford Nanopore Technologies Ltd. announces that Clive G Brown, Chief Technology Officer, will present at the Advances in Genome Biology and Technology (AGBT) conference in Marco Island, Florida, on 17th February 2012 at 11.40am (EST) / 4.40pm (GMT).
The fragrances used in many household and skincare products can cause contact allergy when exposed to oxygen in the air, reveals research from the University of Gothenburg's Faculty of Science in conjunction with the University of Gothenburg to be presented at the dermatologist conference in Gothenburg.
Spectrum Pharmaceuticals, Inc., a commercial-stage biotechnology company with a primary focus in oncology and hematology, and TopoTarget A/S, today announced that the first patient has been dosed in a National Cancer Institute -sponsored Phase 1/2 trial of belinostat in combination with cisplatin, doxorubicin and cyclophosphamide in the first line treatment of advanced or recurrent thymic malignancies.
Scientists have combined two new "designer" forms of aspirin into a hybrid substance that appears more effective than either of its forebears in controlling the growth of several forms of cancer in laboratory tests. Their report on the new NOSH-aspirin, so named because it releases nitric oxide (NO) and hydrogen sulfide (H2S), appears in the journal ACS Medicinal Chemistry Letters.
Using some of the most advanced molecular sequencing tools available to evaluate COVID-19 rapid autopsy tissues, researchers have identified four major regulatory pathways, specific molecular effectors behind COVID-19 symptoms, and differences that drive diverging clinical courses among individual patients.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Brian Jonathan Lipman, MD Po Box 845712, Los Angeles, CA 90084-5712 Ph: (888) 252-2804 | Dr Brian Jonathan Lipman, MD 10001 S Eastern Ave Ste 307, Henderson, NV 89052 Ph: (702) 909-7170 |
News Archive
Oxford Nanopore Technologies Ltd. announces that Clive G Brown, Chief Technology Officer, will present at the Advances in Genome Biology and Technology (AGBT) conference in Marco Island, Florida, on 17th February 2012 at 11.40am (EST) / 4.40pm (GMT).
The fragrances used in many household and skincare products can cause contact allergy when exposed to oxygen in the air, reveals research from the University of Gothenburg's Faculty of Science in conjunction with the University of Gothenburg to be presented at the dermatologist conference in Gothenburg.
Spectrum Pharmaceuticals, Inc., a commercial-stage biotechnology company with a primary focus in oncology and hematology, and TopoTarget A/S, today announced that the first patient has been dosed in a National Cancer Institute -sponsored Phase 1/2 trial of belinostat in combination with cisplatin, doxorubicin and cyclophosphamide in the first line treatment of advanced or recurrent thymic malignancies.
Scientists have combined two new "designer" forms of aspirin into a hybrid substance that appears more effective than either of its forebears in controlling the growth of several forms of cancer in laboratory tests. Their report on the new NOSH-aspirin, so named because it releases nitric oxide (NO) and hydrogen sulfide (H2S), appears in the journal ACS Medicinal Chemistry Letters.
Using some of the most advanced molecular sequencing tools available to evaluate COVID-19 rapid autopsy tissues, researchers have identified four major regulatory pathways, specific molecular effectors behind COVID-19 symptoms, and differences that drive diverging clinical courses among individual patients.
› Verified 7 days ago
James B Gabroy, MD Infectious Disease Medicare: Medicare Enrolled Practice Location: 1535 West Warm Spring Road, Suite 135, Henderson, NV 89014 Phone: 702-450-3385 Fax: 702-898-1699 | |
Dr. Poupak Ziaei, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 2641 W Horizon Ridge Pkwy Ste 100, Henderson, NV 89052 Phone: 702-616-0091 Fax: 702-616-2329 | |
Dr. Jeannette Nee, MD Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 2865 Siena Heights Dr, Suite 331, Henderson, NV 89052 Phone: 702-407-0110 Fax: 702-407-0133 | |
Wen Liang, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 2621 W Horizon Ridge Pkwy, Suite 150, Henderson, NV 89052 Phone: 702-837-6368 Fax: 702-837-0685 | |
Randy James Ip, D.O. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 2865 Siena Heights Dr Ste 331, Henderson, NV 89052 Phone: 702-407-0110 Fax: 702-407-0133 | |
Linda Lou Johnson, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1501 W Sunset Rd, Henderson, NV 89014 Phone: 725-269-7001 Fax: 725-269-7003 | |
Dr. Daejoon Anh, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 2865 Siena Heights Dr Ste 331, Henderson, NV 89052 Phone: 702-407-0110 Fax: 702-407-0133 |